Human peripheral blood was stained with (A) Rabbit anti-Human KLRG1 Monoclonal Antibody (Catalog # MAB70293) or (B) Rabbit IgG control antibody (Catalog # MAB1050) followed by APC-conjugated Anti-Rabbit IgG Secondary ...read more
KLRG1 was detected in immersion fixed paraffin-embedded sections of human tonsil using Rabbit Anti-Human KLRG1 Monoclonal Antibody (Catalog # MAB70293) at 3 µg/mL for 1 hour at room temperature followed by ...read more
KLRG1 (killer cell lectin-like receptor G1), also called MAFA (mast cell function associated), is a 30-38 kDa type II transmembrane inhibitory glycoprotein of the C‑type lectin family, designated CLEC15A. KLRG1 cDNA encodes 195 amino acids (aa) including an intracellular ITIM motif and a 136 aa extracellular domain (ECD) with a single C‑type lectin domain. The human KLRG1 ECD shares 57% and 54% aa identity with mouse and rat KLRG1, respectively. A 189 aa isoform diverges at aa 186. KLRG1 binds E-, N- and R-cadherins and functions as an MHC‑independent means of identifying non-self pathogens and epithelial tumor cells with low E‑cadherin expression. It is expressed as a monomer or disulfide‑linked homodimer on NK and T cell subsets such as tumor-infiltrating lymphocytes.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.